Department of Thoracic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, People's Republic of China.
School of Nursing, Anhui Medical University, Hefei, People's Republic of China.
Cancer Immunol Immunother. 2021 Oct;70(10):2835-2850. doi: 10.1007/s00262-021-02896-6. Epub 2021 Mar 3.
Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), causes high mortality around the world. Previous studies have suggested that the metabolic pattern of tumor is associated with tumor response to immunotherapy and patient's survival outcome. Yet, this relationship in LUAD is still unknown.
Therefore, in this study, we identified the immune landscape in different tumor subtypes classified by metabolism-related genes expression with a large-scale dataset (tumor samples, n = 2181; normal samples, n = 419). We comprehensively correlated metabolism-related phenotypes with diverse clinicopathologic characteristics, genomic features, and immunotherapeutic efficacy in LUAD patients.
And we confirmed tumors with activated lipid metabolism tend to have higher immunocytes infiltration and better response to checkpoint immunotherapy. This work highlights the connection between the metabolic pattern of tumor and tumor immune infiltration in LUAD. A scoring system based on metabolism-related gene expression is not only able to predict prognosis of patient with LUAD but also applied to pan-cancer. LUAD response to checkpoint immunotherapy can also be predicted by this scoring system.
This work revealed the significant connection between metabolic pattern of tumor and tumor immune infiltration, regulating LUAD patients' response to immunotherapy.
肺腺癌(LUAD)是非小细胞肺癌(NSCLC)的一种亚型,在全球范围内导致高死亡率。先前的研究表明,肿瘤的代谢模式与肿瘤对免疫治疗的反应和患者的生存结果有关。然而,这种关系在 LUAD 中尚不清楚。
因此,在这项研究中,我们使用大规模数据集(肿瘤样本,n=2181;正常样本,n=419),根据与代谢相关基因表达分类的不同肿瘤亚型,确定了免疫景观。我们全面关联了代谢相关表型与 LUAD 患者的不同临床病理特征、基因组特征和免疫治疗疗效。
我们证实,激活脂质代谢的肿瘤往往具有更高的免疫细胞浸润和更好的检查点免疫治疗反应。这项工作强调了肿瘤代谢模式与 LUAD 肿瘤免疫浸润之间的联系。基于代谢相关基因表达的评分系统不仅能够预测 LUAD 患者的预后,而且适用于多种癌症。该评分系统还可以预测 LUAD 对检查点免疫治疗的反应。
这项工作揭示了肿瘤代谢模式与肿瘤免疫浸润之间的显著联系,调节了 LUAD 患者对免疫治疗的反应。